Tumor Board
-
The value of MRD assessment in oligometastic colorectal cancer
John Strickler, MD; Tanios S. Bekaii-Saab, MD
-
Updates from ASCO 2026: Does MRD testing present a molecular window of opportunity for pancreatic cancer?
John Strickler, MD; Ryne Ramaker, MD, PhD
-
Colorectal cancer updates from ASCO 2026: Impact of ctDNA and MRD testing on guiding adjuvant chemotherapy and treatment response monitoring
John Strickler, MD; Tanios S. Bekaii-Saab, MD
-
ASCO Update: Daraxonrasib (RMC-6236) for KRAS mutated metastatic pancreatic cancer
John Strickler, MD; Tanios S. Bekaii-Saab, MD
